• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immatics N.V. - Ordinary Shares (NQ:IMTX)

9.400 +0.670 (+7.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immatics N.V. - Ordinary Shares

< Previous 1 2 Next >
Immatics Appoints Venkat Ramanan as Chief Financial Officer
October 01, 2025
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Second Quarter 2025 Financial Results and Business Update
August 13, 2025
From https://immatics.com/
Via GlobeNewswire
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
May 31, 2025
From https://immatics.com/
Via GlobeNewswire
Immatics Announces First Quarter 2025 Financial Results and Business Update
May 13, 2025
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
April 23, 2025
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Full Year 2024 Financial Results and Business Update
March 27, 2025
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
November 18, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
November 08, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Pricing of $150 Million Public Offering
October 10, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Proposed $150 Million Public Offering
October 10, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
October 10, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
October 04, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
September 16, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
September 06, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Second Quarter 2024 Financial Results and Business Update
August 13, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Appoints Alise Reicin to Board of Directors
July 31, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
July 18, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces First Quarter 2024 Financial Results and Business Update
May 14, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Full Year 2023 Financial Results and Corporate Update
March 21, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Pricing of $175 Million Public Offering
January 17, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Proposed Public Offering
January 17, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Third Quarter 2023 Financial Results and Business Update
November 14, 2023
From https://immatics.com/
Via GlobeNewswire
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
November 08, 2023
From https://immatics.com/
Via GlobeNewswire
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
October 24, 2023
From https://immatics.com/
Via GlobeNewswire
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
September 11, 2023
Via ACCESSWIRE
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
September 11, 2023
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Second Quarter 2023 Financial Results and Business Update
August 17, 2023
From https://immatics.com/
Via GlobeNewswire
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
August 10, 2023
From https://immatics.com/
Via GlobeNewswire
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
July 24, 2023
From https://immatics.com/
Via GlobeNewswire
Immatics Announces First Quarter 2023 Financial Results and Business Update
May 16, 2023
From https://immatics.com/
Via GlobeNewswire
< Previous 1 2 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  246.45
+0.02 (0.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap